

24 January 2025

Treatments on Asthma

I have a freedom of information request that I need your help with. Could you please answer the questions below:

1. How many patients have been treated (for any condition) in the last 4 months with:

Adult Respiratory Service

- **Benralizumab** 137
- **Dupilumab** 76
- **Omalizumab** 53
- **Reslizumab** 0
- **Mepolizumab** 309
- **Tezepelumab** 24

Paediatric Service

- **Benralizumab** 0
- **Dupilumab** <5
- **Omalizumab** 0
- **Reslizumab** 0
- **Mepolizumab** 9
- **Tezepelumab** 0

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

Adult Respiratory Service

- **Age 6-11**
- **Age 12-17**
- **Age 18 and above** 599

Paediatric Service

- **Age 6-11** 5
- **Age 12-17** 6
- **Age 18 and above** <5

3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

Adult Respiratory Service

- **Dupilumab** 0
- **Omalizumab** 0

24 January 2025

Paediatric Service

- **Dupilumab** <5
- **Omalizumab** 0

4. **How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:**

Adult Respiratory Service

Not applicable to Adult Respiratory Service, which does not primarily treat chronic sinusitis and nasal polyps. Therefore, this would not be their primary indication for biologics.

Paediatric Service

Not relevant to this service

- **Benralizumab**
- **Dupilumab**
- **Omalizumab**
- **Reslizumab**
- **Mepolizumab**
- **Tezepelumab**

ENT Service

ENT do not prescribe biologics directly. If there are patients with chronic sinusitis or polyps, discussions are held with respiratory or immunology colleagues and patients are managed via those services with ENT input as deemed appropriate after Multi-Disciplinary Team discussions.

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.